top of page
The Sound of Evolution
Cangrelor
Mechanism of action:
Cangrelor is a platelet P2Y12 inhibitor and is an analog of adenosine triphosphate (ATP). During platelet activation, adenosine diphosphate (ADP) binds to the P2Y12 receptor on the platelet surface, promoting activation and conformational change of the GPIIb/IIIa receptor, making it more likely to bind fibrinogen and allowing platelets to aggregate and form thrombi. Cangrelor reversibly inhibits the platelet P2Y12 receptor, suppresses ADP-mediated signal transduction, and prevents thrombus formation.
Reference(s):
1. Keating GM et al. (2015). Cangrelor: A review in percutaneous coronary intervention. Drugs.
2. Fugate SE et al. (2006). Cangrelor for treatment of coronary thrombosis. Ann Pharmacother.
bottom of page